Advertisement
HTDS increased the number of its authorized shares to 8.8 billion to accommodate the merger and the size of the new medical company from middle east/Israel, and expand the Melem Secrets cosmetics line. HTDS will publish full details about the new company as soon as both sides finalize the merger. Filings from Florida State are filed with Pink Sheets. Obviously if the merger does not happen the stock will be returned to the treasury of HTDS.
Advertisement
The new merger candidate operates an obstetrician type medical company. This Middle Eastern company focuses on treatment of pre-term labor and induction of labor. The company seeks cooperation with HTDS to co-develop this enzyme and meet GMP and FDA enzyme/cytokines production; as well as to develop Phase II clinical trials in China and share production and marketing with HTDS.
Pre-term birth affects 11 percent of births in the USA each year, and accounts for 75% of infant deaths and 50% of the long-term neurological handicaps, including cerebral palsy, blindness, deafness, and developmental defects. The direct care in Neonatal Intensive Care Units (NICU) costs staggering $45 billion to $65 billion in the developed world, treating an estimated 1.5 million pre-term infants, with total of about 4.5 million NICU hospitalization weeks.
To be included in HTDS' email database for press releases and industry updates, please subscribe at or opt in with your email address at this link: http://www.minamargroup.com/updates/.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiries only, please contact [email protected]; for any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
